ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting

    Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study

    Ghada Ahmed1, Sandra L Goss1, Cheri E Klein1, Neelufar Mozaffarian2, Gurjit S. Kaeley3 and Walid Awni1, 1AbbVie Inc., North Chicago, IL, 2Eli Lilly, San Diego, CA, 3College of Medicine, University of Florida, Jacksonville, FL

    Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
  • Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting

    Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients

    Eric Elkin1, Martin J. Bergman2, Tripthi Kamath3, Sarika Ogale3, Adam Turpcu3, Kristin King4, Jae Oh4, Monarch Shah1 and Max I. Hamburger5, 1ICON Clinical Research, San Francisco, CA, 2Taylor Hospital, Ridley Park, PA, 3Genentech, South San Francisco, CA, 4ICON Late Phase and Outcomes Research, San Francisco, CA, 5Rheumatology Associates, Melville, NY

    Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
  • Abstract Number: 1469 • 2013 ACR/ARHP Annual Meeting

    Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial

    Jacques-Eric Gottenberg1, Olivier Brocq2, Aleth Perdriger3, Slim Lassoued4, Jean-Marie Berthelot5, Daniel Wendling6, Liana E. euller-Ziegler7, Martin Soubrier8, Christophe Richez9, Bruno Fautrel10, Arnaud L. Constantin11, Xavier Mariette12, Jacques Morel13, Melanie Gilson14, Grégoire Cormier15, Jean Hugues Salmon16, Stephanie Rist17, Frédéric Liote18, Hubert Marotte19, Christine Bonnet20, Christian Marcelli21, Jeremie Sellam22, Olivier Meyer23, Elisabeth Solau-Gervais24, Sandrine Guis25, Jean-Marc Ziza26, Charles Zarnitsky27, Isabelle Valckenaere28, Olivier Vittecoq29, Alain Saraux30, Yves-Marie Pers31, Martine Gayraud32, Gilles Bolla33, Pascal Claudepierre34, Marc Ardizzone35, Emmanuelle Dernis36, Maxime A. Breban37, Olivier Fain38, Jean-Charles Balblanc39, Ouafaa Aberkane1, Marion Vazel1, Christelle Back1, Elodie Perrodeau40, Philippe Ravaud41 and Jean Sibilia42, 1Strasbourg University Hospital, Strasbourg, France, 2Hospital of Princesse Grâce de Monaco, Monaco, France, 3Rheumatology, Hôpital Sud, Rennes, France, 4Cahors Hospital, Cahors, France, 5Rheumatology Unit, Nantes University Hospital, Nantes, France, 6Rheumatology, University Hospital, Besancon, France, 7Service de Rhumatologie, L Archet Hospital (University), Nice CEDEX 3, France, 8Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 9Pellegrin Hospital, Bordeaux, France, 10Rheumatology, UPMC - Paris 6 University, Paris, France, 11Rheumatology, Purpan University Hospital, Toulouse, France, 12Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 13Montpellier University Hospital, Montpellier, France, 14CH Grenoble Hopital Sud, Grenoble, France, 15CHD Les Oudairies, LA ROCHE SUR YON, France, 16Reims Hospital, Reims, France, 17Rheumatology, Orleans Hospital, Orleans, France, 18Hôpital Lariboisière, Paris, France, 19INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, 20department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, 21Rheumatology Department, Caen University Hospital, CAEN, France, 22Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, 23Rheumatology, Hopital Bichat, Paris, France, 24Poitiers University Hospital, Poitiers, France, 25Rheumatology1, CRMBM UMR CNRS 7339, Aix Marseille Univ; AP-HM, Marseille, France, 26Rheumatology, Croix Saint Simon Hospital, Paris, France, 27Rheumatology, CH du Havre, Le Havre, France, 28Nancy University Hospital, Nancy, France, 29RouenUniversity Hospital, Rouen, France, 30Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, 31Department of Immuno-Rhumatology, CHU Lapeyronie, Montpellier, France, 32Institut Montsouris, Paris, France, 33Cannes Hospital, Cannes, France, 34Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 35Mulhouse Hospital, Mulhouse, France, 36Le Mans Hospital, Le Mans, France, 37Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, 38Internal Medicine, Jean Verdier Hospital, Bondy, France, 39Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, 40Epidemiology, Hotel Dieu, Paris, France, 41Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 42Rheumatology, CHU Hautepierre, Strasbourg, France

    Background/Purpose: TNF inhibitors often represent the 1st biologic prescribed to patients with rheumatoid arthritis (RA). Approximately one third of patients fail to respond. However, therapeutic…
  • Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis

    Paul A. MacMullan1,2, Anne M. Madigan1, Laura J. Durcan3, Karl Egan2, Paola M. Bagaglia1, Dermot Kenny4 and Geraldine M. McCarthy1, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Cardiovascular Biology Laboratory, RCSI, Dublin, Ireland, 3Rheumatology, Mater Misercordiae University Hospital, Dublin 7, Ireland, 4Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland

    Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…
  • Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Maria A. Lopez-Olivo1, Maria E. Suarez-Almazor2 and Mahesh Bavineni3, 1General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, 2The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Internal Medicine, Louisiana State University Lafayette, Lafayette, LA

    Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
  • Abstract Number: 1473 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects

    Ilinca D. Metes1, Douglas W. Chew1, Aarat M. Patel1, G.K. Balasubramani2, S. Louis Bridges Jr.3, Jeffrey R. Curtis4, Stephen R. Wisniewski2, Larry W. Moreland5 and Marc C. Levesque6, 1Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 3Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Amyloidosis is often due to an underlying inflammatory disorder, such as rheumatoid arthritis (RA), with organ deposition of serum amyloid A (SAA).  Oral disease…
  • Abstract Number: 1475 • 2013 ACR/ARHP Annual Meeting

    Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis

    Glen S. Hazlewood1, J. Carter Thorne2, Janet E. Pope3, Juan Xiong4, Gilles Boire5, Boulos Haraoui6, Carol A. Hitchon7, Edward C. Keystone8, Diane Tin9 and Vivian P. Bykerk10, 1Medicine, University of Calgary, Calgary, AB, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3St Joseph Health Care, London, ON, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 6Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 7Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 8Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 10Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: To determine the comparative survival of initial treatment with subcutaneous (sc) methotrexate (MTX) versus oral MTX for patients with early rheumatoid arthritis (ERA) in…
  • Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting

    Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study

    Arthur N. Lau1, Alpesh Shah2, Melissa Deamude3, Cynthia Mech4, Robert Bensen5 and William G. Bensen6, 1Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, 3Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, 4Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 5Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 6Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada

    Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
  • Abstract Number: 1477 • 2013 ACR/ARHP Annual Meeting

    A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab

    Fumihiko Miyoshi1, Kyoko Honne2, Seiji Minota3, Masato Okada4, Noriyoshi Ogawa5 and Toshihide Mimura6, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, 3Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan, 4Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 5Rheumatology, Hamamatsu University School of Medicine, Hamamatsu, Japan, 6Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Treatment using biologics is widely used for rheumatoid arthritis (RA) in these days. Prediction of the clinical response to biologics prior to the administration…
  • Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study

    Thomas W.J. Huizinga1, Philip G. Conaghan2, Emilio Martin-Mola3, Georg Schett4, Howard Amital5, Ricardo M. Xavier6, Orrin Troum7, Maher Aassi8, Corrado Bernasconi9 and Maxime Dougados10, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 6Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 7University of Southern California School of Medicine, Santa Monica, CA, 8F. Hoffmann-La Roche, Basel, Switzerland, 9Consultant, Basel, Switzerland, 10Cochin Hospital, Paris, France

    Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…
  • Abstract Number: 1438 • 2013 ACR/ARHP Annual Meeting

    Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi

    Leslie R. Harrold1, George W. Reed2, Robert P. Magner1, Ashwini Shewade3, Ani John3, Jeffrey D. Greenberg4 and Joel M. Kremer5, 1University of Massachusetts Medical School, Worcester, MA, 2CORRONA, Inc., Southborough, MA, 3Genentech Inc., South San Francisco, CA, 4NYU Hospital for Joint Diseases, New York, NY, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: In patients (pts) who have failed 1 or more TNF-α inhibitors (TNFi), there is little data to guide clinical decision making in terms of…
  • Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting

    Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis

    Charles Inderjeeth1, Andrew Redfern1, Michael Huang2, Yun Hardiman2, Theresa Grant2, Lawrence C. Fritz2, David Fuller3, David Haughey4 and Mark C. Totoritis2, 1Linear Clinical Research Ltd, Perth, Australia, 2Santarus, Inc., San Diego, CA, 3INC Research, Inc., New South Wales, Australia, 4ICON Development Solutions, Whitesboro, NY

    Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
  • Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting

    Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs

    Sang Jin Lee1,2, Kyung Rok Kim3, Sang Hyun Joo3, Jae Myung Lee3, In Ah Choi3, Joo Youn Lee2, Hyun Jung Yoo2, Eun Young Lee4, Eun Bong Lee1, Won Park5, Sung Hwan Park6, Seung-Cheol Shim7, Dae-Hyun Yoo8, Han Joo Baek9, Hyun Ah Kim10, Soo Kon Lee11, Yun Jong Lee1, Young Eun Park12, Hoon-Suk Cha13 and Yeong Wook Song2,3, 1Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, 2Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 4Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, 7Medicine, Rheumatology, Eulji University, Daejeon, South Korea, 8Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, 11Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 12Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, 13Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
  • Abstract Number: 1441 • 2013 ACR/ARHP Annual Meeting

    Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis

    Maria Victoria Hernández1, Javier Narvaez2, Raimon Sanmarti3, Delia Reina4, Cesar Diaz-Torne5, Berta Magallares5, Arturo Rodriguez de la Serna5, José María Llobet5, Hector Corominas4 and Joan Miquel Nolla2, 1Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 5Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: To analyze the efficacy and identify predictors of response to tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods: A multicenter ambispective observational study…
  • Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting

    Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with  Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry

    HCB Leffers1,2, Mikkel Østergaard3, Bente Glintborg4, Niels Steen Krogh5, Ulrik Tarp6, Tove Lorenzen7, Annette Hansen8, Lene Dreyer9 and Merete L. Hetland3, 1DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, 2Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, 3Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 4Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 5ZiteLab ApS, Copenhagen, Denmark, 6Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 7Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 8Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 9Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark

    Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…
  • « Previous Page
  • 1
  • …
  • 2151
  • 2152
  • 2153
  • 2154
  • 2155
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology